ITM Entered into a Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 to Treat Solid Tumors
Shots
- ITM to supply its n.c.a. 177Lu for the clinical development of Y-mAbs’ GD2-SADA: 177Lu-DOTA complex for GD2+ solid tumors
- The P-I study of GD2-SADA is expected to be planned for 2022. GD2-SADA: 177Lu-DOTA Complex, 2-step radioimmunotherapy that can be given as an IV inf. while 177Lu-DOTA Complex targets the prior administered tumor-binding Ab construct GD2-SADA & consists of chelator (DOTA) & ITM's n.c.a. 177Lu to delivery therapeutic radiation of n.c.a. 177Lu to the tumor-site & kill malignant cells
- N.c.a. 177Lu is a highly pure, market-approved form of the beta-emitting radioisotope 177Lu that has been used in multiple cancer treatments. It can be linked to a no. of tumor-specific targeting molecules for cancers
Ref: GlobalNewswire | Image: ITM
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
